🇺🇸 NBIX — Neurocrine Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

159,76 USD

Máx. histórico

185,50

98 días

Caída desde máximo

-13,88%

Rango 52 semanas

122,14 – 186,12

Variación hoy

-3,79%

Cierre anterior

166,05

Rango de hoy

159,53 – 167,68

Volumen hoy

1.482.485

Peor caída histórica

-97,21%

15/03/2006 → 12/11/2009

Recuperado en 2911 días

Volatilidad anualizada ⓘ

61,30%

Información
Nombre completo
Neurocrine Biosciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
2.500
PER ⓘ
23,70 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
207,50 USD (puede no estar actualizado)
Primera cotización
23/05/1996
Precio actualizado
hace 5 horas
Sobre la empresa

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
12/05/2000 20,25 21,25 20,06 20,81 +1,52% 5,86% 29.300
11/05/2000 20,50 22,00 20,00 20,50 +1,55% 9,76% 79.600
10/05/2000 20,00 20,44 19,75 20,19 -2,71% 3,44% 136.600
09/05/2000 21,06 22,00 20,00 20,75 +1,22% 9,50% 158.300
08/05/2000 20,75 21,38 20,19 20,50 -5,20% 5,72% 84.000
05/05/2000 19,31 21,63 19,00 21,63 +10,19% 13,59% 261.600
04/05/2000 21,00 21,00 19,38 19,63 +0,64% 7,74% 110.000
03/05/2000 22,38 22,38 19,25 19,50 -11,36% 13,97% 58.800
02/05/2000 20,50 22,56 20,00 22,00 +1,15% 12,50% 102.600
01/05/2000 21,63 22,50 20,13 21,75 +2,35% 10,98% 34.700
28/04/2000 20,00 21,63 18,50 21,25 +14,86% 15,63% 54.500
27/04/2000 20,00 20,00 18,38 18,50 -6,62% 8,13% 119.100
26/04/2000 20,00 21,50 19,75 19,81 +0,32% 8,75% 30.900
25/04/2000 19,06 20,88 18,38 19,75 +7,48% 13,11% 218.900
24/04/2000 19,63 19,63 17,75 18,38 -6,96% 9,55% 92.800
20/04/2000 22,13 22,63 19,75 19,75 -10,23% 12,99% 152.000
19/04/2000 19,88 22,94 19,38 22,00 +12,82% 17,92% 246.900
18/04/2000 16,69 19,63 16,50 19,50 +16,85% 18,73% 192.500
17/04/2000 15,75 17,50 13,94 16,69 +0,38% 22,62% 277.500
14/04/2000 18,25 18,31 15,13 16,63 -13,64% 17,47% 259.900
13/04/2000 18,66 19,38 18,00 19,25 +3,36% 7,37% 294.700
12/04/2000 21,00 21,00 18,00 18,63 -6,29% 14,29% 170.200
11/04/2000 20,44 21,19 19,25 19,88 -2,75% 9,48% 229.700
10/04/2000 21,63 21,69 20,00 20,44 -0,30% 7,80% 260.200
07/04/2000 22,75 23,00 19,50 20,50 +5,47% 15,38% 304.200
06/04/2000 19,88 21,00 18,50 19,44 -13,37% 12,58% 1.251.700
05/04/2000 21,06 22,44 18,00 22,44 +2,87% 21,07% 771.400
04/04/2000 22,69 23,13 18,88 21,81 +3,87% 18,73% 329.500
03/04/2000 23,38 25,88 20,75 21,00 -9,68% 21,93% 159.300
31/03/2000 23,13 25,00 23,00 23,25 -0,53% 8,65% 234.300